Over two decades of history behind our innovation in pain
1 min read
At Vertex, we’re fearless in our pursuit of innovation, and we’ve spent over 20 years researching potential medicines to treat pain.
A nephrologist’s perspective on APOL1-mediated kidney disease
2 min read
Dr. Ogo Egbuna leads clinical development for our genetic kidney disease programs. Learn more about APOL1-mediated kidney disease from a nephrologist’s perspective.
Vertex researchers win Breakthrough Prize in Life Sciences
3 min read
We are relentless in our quest to improve the lives of people living with serious diseases. Thanks to the dedication of teams led by Paul Negulescu, Sabine Hadida and Fred Van Goor, our medicines have profoundly impacted the cystic fibrosis community, earning recognition such as the prestigious Breakthrough Prize.
Advocating for alternatives: The Rhodes family story
1 min read
Kerri and Taylor Rhodes felt helpless as they watched their son struggle with substance use disorder after being prescribed an opioid to help with postoperative pain. When their daughter faced the same procedure years later, the family was determined to find a different way to manage her pain.
Targeting genetic kidney disease
1 min read
APOL1-mediated kidney disease (AMKD) is a serious disease with a high unmet need — exactly the type of problem that fits our research strategy. Hear from experts in our AMKD podcast episode, in partnership with Bloomberg Media Studios.
Reflecting on 2023 — The Vertex Foundation
3 min read
When reflecting on 2023, it is clear that the Vertex Foundation had another strong year of impact through its nonprofit partnerships in our amazing communities and with the unwavering support of Vertexians.
Research and beyond: Our commitment to the beta thalassemia community
3 min read
We’ve been working with the beta thalassemia community since the inception of our research program in 2015. Learn more about our efforts and commitments around the globe.
Apply now! Vertex Foundation Scholarship applications open
1 min read
The Vertex Foundation Scholarship helps eligible people with cystic fibrosis and their families in the U.S. and Canada pursue higher education degrees. Recipients will be awarded $5,000 USD/CAD toward the 2024-2025 academic year.
Game changers
3 min read
Diana Cruz Solash, Vice President of Talent and ID&E, shares game-changing insights from our seventh annual ID&E Week.
Nancy Thornberry
Director
Nancy Thornberry
Director
Scientific & Technology Committee, Member
Ms. Thornberry joined our board in 2023. She founded and served as Chief Executive Officer of Kallyope, a clinical stage biotechnology company, from its launch in 2015 until 2021, and remains on Kallyope’s board of directors and is Chair of Research and Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical research in diabetes, obesity and women’s health. Among her many notable scientific accomplishments, Ms. Thornberry initiated and led Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery and commercialization of JANUVIA® for the treatment of type 2 diabetes. She also identified the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award from the American Chemical Society, and in 2011, the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves on the board of directors of Schrödinger, Inc., Denali Therapeutics Inc. and the New York Genome Center. She serves as an advisor to GV (Google Ventures) and is a member of NYC’s Mayor’s Life Sciences (LifeSciNYC) Advisory Council. Ms. Thornberry holds a Bachelor of Science degree in chemistry and biology from Muhlenberg College.
Ms. Thornberry joined our board in 2023. She founded and served as Chief Executive Officer of Kallyope, a clinical stage biotechnology company, from its launch in 2015 until 2021, and remains on Kallyope’s board of directors and is Chair of Research and Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical research in diabetes, obesity and women’s health. Among her many notable scientific accomplishments, Ms. Thornberry initiated and led Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery and commercialization of JANUVIA® for the treatment of type 2 diabetes. She also identified the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award from the American Chemical Society, and in 2011, the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves on the board of directors of Schrödinger, Inc., Denali Therapeutics Inc. and the New York Genome Center. She serves as an advisor to GV (Google Ventures) and is a member of NYC’s Mayor’s Life Sciences (LifeSciNYC) Advisory Council. Ms. Thornberry holds a Bachelor of Science degree in chemistry and biology from Muhlenberg College.